Detalles de la búsqueda
1.
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Drug Metab Dispos
; 43(9): 1360-71, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149830
2.
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Invest New Drugs
; 32(5): 825-37, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919854
3.
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs.
Int J Pharm
; 526(1-2): 443-454, 2017 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28473237
4.
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Clin Cancer Res
; 20(14): 3763-74, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24850847
5.
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
Mol Cancer Ther
; 13(6): 1442-56, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24688048
6.
Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.
J Pharm Sci
; 100(6): 2498-507, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21213309
7.
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Bioorg Med Chem Lett
; 16(24): 6293-7, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17005393
Resultados
1 -
7
de 7
1
Próxima >
>>